

RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP: _____

32692

Customer Number

Patent
Case No.: 58077US003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: ROEHRIG, MARK A

Application No.: 10/823328 Confirmation No.: 4482

Filed: 13-APR-2004

Title: TRANSDERMAL DRUG DELIVERY DEVICE WITH TRANSLUCENT
INORGANIC BARRIER LAYER

AMENDMENT AND RESPONSE UNDER 37 CFR § 1.116

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR § 1.8(a)]

I hereby certify that this correspondence is being:

transmitted to United States Patent and Trademark Office on the date shown below via the Office electronic filing system.

deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at 571-273-8300.

Date

June 16, 2010

/Chris Johnson/

Signed by: Chris Johnson

Dear Sir:

This is in response to the outstanding Office Action, dated March 16, 2010, in the above-identified application.

Fees

Any required fee will be made at the time of submission via EFS-Web. In the event fees are not or cannot be paid at the time of EFS-Web submission, please charge any fees under 37 CFR § 1.17 which may be required to Deposit Account No. 13-3723.

Please charge any fees under 37 CFR §§ 1.16 and 1.17 which may be required to Deposit Account No. 13-3723.

Please charge any additional fees associated with the prosecution of this application to Deposit Account No. 13-3723. This authorization includes the fee for any necessary extension of time under 37 CFR § 1.136(a). To the extent any such extension should become necessary, it is hereby requested.

Please credit any overpayment to the same deposit account.